Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | VHL | P40337 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | CCKBR | P32239 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | YAP1 | P46937 | 2/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.34 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | QDPR | P09417 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15083921 | 0.88 | CACNA1B (0.38) | CACNA1BMAPK1VHLCCKBRYAP1 | |
| SCHEMBL16622336 | 0.87 | PREP (0.40) | CACNA1BMAPK1VHLNAMPTCCKBR | |
| SCHEMBL15083925 | 0.85 | CTSC (0.39) | CACNA1BMAPK1VHLCCKBRKMT2A | |
| SCHEMBL14822366 | 0.85 | CACNA1B (0.40) | CACNA1BMAPK1CCKBRKMT2AYAP1 | |
| SCHEMBL15084107 | 0.84 | CACNA1B (0.39) | CACNA1BMAPK1NAMPTCCKBRKMT2A | |
| SCHEMBL15083997 | 0.84 | CTSS (0.41) | CACNA1BMAPK1CCKBRKMT2AYAP1 | |
| SCHEMBL14822357 | 0.84 | CACNA1B (0.39) | CACNA1BMAPK1CCKBRKMT2AYAP1 | |
| SCHEMBL15084021 | 0.83 | GPR119 (0.44) | — | |
| SCHEMBL15084109 | 0.82 | CTSC (0.41) | CACNA1BMAPK1KMT2ACTSC | |
| SCHEMBL15083924 | 0.82 | MCL1 (0.39) | CTSC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130172327-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172327-A1 | SUBSTITUTED N- [1-CYANO-2- (PHENYL) ETHYL] -2-AZABICYCLO [2.2.1] HEPTANE-3-CARBOXAMIDE INHIBITORS OF CATHEPSIN C | CTSS, CTSB, CTSG | CACNA1B 1227/4885MAPK1 3146/4885VHL 2349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.